CellProthera is a biotech company, incorporated in April 2008, and intended for the development, registration and marketing of innovative therapeutic solutions for the regeneration of organs damaged by disease or trauma from autologous blood peripheral stem cells.


CellProthera focuses on the use of blood peripheral stem cells for cardiac diseases and is currently developing an innovative therapeutic concept of functional regeneration of the damaged heart muscle after myocardial infarction (AMI). By injection of a graft of autologous CD34 + cell previously selected and expanded  – ProtheraCytes®- in the myocardial muscle, the recovery of the cardiac function allows the patients to have a normal life again.   ProtheraCytes® is now registered as an ATMP – Advanced Therapy Medicinal Product – within the classification of a Tissue Engineered product by the European Medicines Agency.